SUCCIPRO
About
Succipro is a spin-off from the Pere i Virgili Health Research Institute (IISPV) and the Rovira i Virgili University, dedicated to creating innovative pharmaceutical solutions for the treatment of inflammatory and metabolic diseases. They work to transform pioneering scientific discoveries into therapies that improve the quality of life for patients.
Succipro stands out for its first-in-class therapies (i.e., the first in their category), leading innovation in drug development to address unmet medical needs. Their research focuses on: Succinic Acid as a therapeutic target: A pioneering strategy for the treatment of metabolic diseases. Personalized therapy: The application of biomarkers to design treatments tailored to the specific needs of each patient. Safety and efficiency: A commitment to creating drugs that minimize adverse effects, always prioritizing patient safety.